Skip to main content
Motif

The biomarker intelligence platform

Find the biomarkers that matter

Motif turns literature into structured, cross-referenced, cited biomarker associations. Effect sizes, p-values and context, with every claim linked to the paper it came from.

The biomarker that changes your research may already be published.

See what it extracts →

$3 one-time to start. No subscription.

An animation of a Motif run: the query "Find biomarkers for CAR-T resistance in solid tumors" is typed, five steps complete in turn (searching papers, screening them for relevance, extracting biomarker associations, generating a report, and building a knowledge graph), and the panel resolves into a graph linking CAR-T resistance to PD-1, CTLA-4, TILs, CD8+ T cells, T cell exhaustion and an epigenetic barrier score.

Every entity resolved against

  • 53

    reference databases every entity is resolved against

  • Full text

    tables and figures included, not abstracts alone

  • Private

    organization knowledge graph on every plan

  • Cited

    every finding linked back to its source paper

How it works

Reading papers gives you impressions. Extraction gives you data.

Impressions are hard to compare, aggregate or defend. Motif produces structured data you can filter, evidence grades you can justify, and attribution you can verify.

Extraction

Structured findings, not summaries

Every association carries its effect size, confidence interval, p-value, sample size and study design, pulled from full text, tables and figures, not just abstracts.

  • Effect sizes, intervals, p-values and sample sizes when the paper reports them
  • Findings tied back to the source paper and PMID
  • Full text, tables and figures, not abstracts alone

The Association Library, showing three extracted findings. PD-L1 TPS at or above 50 percent predicts improved progression-free survival on pembrolizumab versus chemotherapy in untreated non-small-cell lung cancer, hazard ratio 0.50 with a 95 percent confidence interval of 0.37 to 0.68, p below 0.001, n=305, from a randomised controlled trial, graded High certainty. Neurofilament light chain in cerebrospinal fluid is associated with faster motor progression in early Parkinson's disease, beta 0.31 per standard deviation, graded Moderate. KRAS G12C co-mutation confers resistance to erlotinib in EGFR-mutant lung adenocarcinoma, hazard ratio 1.74, graded Low. Each finding carries the paper it came from and its PubMed identifier.

Cross-referencing

Grounded to the reference databases, not to a guess

Each entity is resolved against 53 authoritative databases, so a name in a paper becomes an accession you can look up, and a mismatch becomes visible instead of silent.

  • Genes, proteins, diseases, drugs, pathways and related biomarker types
  • Linked to UniProt, MONDO, ClinVar, CIViC, gnomAD, Reactome and more
  • Accessions and definitions travel with the finding

A cross-reference panel for the gene ERBB2, also known as HER2, matched against four of Motif's 53 reference databases. UniProt gives accession P04626, reviewed in Swiss-Prot, organism Homo sapiens. ClinVar reports expert-panel review status with a pathogenic classification for ERBB2 amplification. CIViC records evidence level B, predictive significance, in breast carcinoma. The FDA record lists trastuzumab, indicated for HER2-positive breast cancer, approved in 1998.

Your graph

A graph that compounds with every query

A list of 200 papers tells you what exists. A graph tells you how it connects. Each paper extends your organization's graph, and it stays visible only to you.

  • Relationships such as inhibits, activates, associated with and predictive of
  • Filter by context, species, study design or certainty
  • Export formats from BibTeX to Neo4j

A biomarker knowledge graph centred on EGFR in lung cancer. EGFR is associated with lung cancer and predicts sensitivity to erlotinib, while KRAS confers resistance to it. TP53, PD-L1 and IL-6 are each associated with lung cancer, EGFR upregulates PD-L1, and miR-21 correlates with EGFR.

Evidence you can defend

A case report and a 10,000-patient trial are not equal evidence

PubMed treats them the same. Motif assigns a GRADE-adapted certainty to every finding and records study design and statistics so you can see why a claim earned its grade.

An evidence certainty panel adapted from GRADE. The finding is Moderate certainty, with study design, sample size, effect size and risk-of-bias summary shown so a reader can see why the grade landed where it did.

A discordant evidence panel for tumour mutational burden as a predictor of overall survival. One study of 810 patients reports a hazard ratio of 0.61 with a 95 percent confidence interval of 0.44 to 0.85. Another study of 442 patients reports a hazard ratio of 1.28 with a confidence interval of 0.98 to 1.67. Motif classifies the statistical conflict as incompatible, because the confidence intervals exclude one another, and resolves it as context-dependent: the effect differs by disease context, melanoma versus colorectal cancer.

When studies disagree, Motif separates a real contradiction from a difference in context, and shows whether the confidence intervals actually exclude one another.

Who Motif is for

Built for people who have to defend the citation

  • Translational scientists

    Move from a pile of PDFs to a filterable evidence table you can defend in a review meeting.

  • Precision medicine researchers

    See which biomarkers hold up across contexts, and which only worked in one cohort.

  • Companion diagnostic teams

    Assemble graded, cited evidence packages with the study design and risk of bias attached.

Pricing

Start for $3, once

No trial clock, no subscription to cancel. Build your first knowledge graph and decide afterwards.

  • Starter

    $3 (one-time)

    For getting started

  • Pro

    $30

    For regular research

  • Max

    $100

    For large-scale research

  • Enterprise

    Custom

    For team collaboration

Compare plans in full →

Start building your biomarker graph

Run one query and see the evidence come back structured, graded and cited.